Table 1. Short-term effects of medical treatment in chronic post-embolic pulmonary hypertension
TreatmentAdministrationFirst author [Ref.]StudyDuration monthsPatients nNYHA-FC6MWD mEffect mPVR dyn·s−1·cm−5Effect %
Epoprostenoli.v.Cabrol [6]323III–IV280±112+6629±7#,¶-21
TreprostinilSubcutaneouslySkoro-Sajer [7]6 or 1925III–IV260±111+59924±347-13
IloprostInhaledOlschewski [8]RCT357III–IVNAnsNAns
SildenafilBy mouthGhofrani [9]612ns312±30+541935±228+-30
SildenafilBy mouthReichenberger [10]3104II–IV310±11+51863±38-12
SildenafilBy mouthSuntharalingam [11]RCT319II–III339±58+18 (ns)734±363-27
BosentanBy mouthHoeper [12]319II–IV340±102+73914±329-33
BosentanBy mouthHughes [13]320II–IV262±106+451165±392#-21
BosentanBy mouthBonderman [14]616II–IV299±131+92712±213NA
BosentanBy mouthSeyfarth [15]612III319±85+721008±428NA
BosentanBy mouthJaïs [16]RCT4157II–III342±84+2 (ns)783-24
RiociguatBy mouthGhofrani [17]OL341II–III390 (330–441)+55691 (533–844)-29
RiociguatBy mouthGhofrani [18]RCT4261II–III349+46785-31
  • Data are presented as mean±sd or median (interquartile range), unless otherwise stated. NYHA-FC: New York Heart Association functional class; 6MWD: 6-min walking distance; PVR: pulmonary vascular resistance; RCT: randomised controlled trial; OL: open label; NA: not available; ns: not significant. #: total PVR; : in Woods Units·m2; +: in dyn·s−1·cm−5·m−2.